Brief: Akari Therapeutics Reports Q1 2022 Results
20/07/2022 11:55
July 20 (Reuters) - Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS REPORTS FIRST QUARTER 2022 FINANCIAL
RESULTS
AND HIGHLIGHTS RECENT PIPELINE PROGRESS
* AKARI THERAPEUTICS PLC QTRLY LOSS PER ORDINARY SHARE
(BASIC AND
DILUTED) $0.00
Source text for Eikon: ID:nGNX5ZhBJT
Further company coverage: AKTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics